Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
Drug development; Viral infection
Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Br J Cancer. 2020 Sep;123:694–697.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/6429
This item appears in following collections
The following license files are associated with this item: